*ST HILE plans to acquire 60% of shares in a Dental Restoration|Prosthodontics materials company for 93.6 million yuan, aiming to complete its industrial chain and strengthen overseas business layou…

Source: Announcement of *ST Haili Haili Biology regarding its controlling subsidiary's acquisition of equity in Hunan Zerdun New Materials Co., Ltd.

DentalGoodNews | May 29, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. (hereinafter referred to as "ST HILE") announced that its controlling subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd. (hereinafter referred to as "Ruisheng Biology"), plans to acquire 60% equity of Hunan Zerdun New Materials Co., Ltd. (hereinafter referred to as "Zerdun") with its own/self-raised funds of RMB 93.6 million. Upon completion of the transaction, Zerdun will become a controlled subsidiary of Ruisheng Biology and a second-tier subsidiary of ST HILE.

According to the announcement, Zeldent specializes in the research, development, manufacturing, and sales of zirconia blocks for all-ceramic dental prostheses and other dental restorative materials. Its flagship product, the 3D-Pro Multilayer Zirconia Block, utilizes a domestically leading glue-free manufacturing process and features gradual transitions in strength, translucency, and color. The company has obtained both U.S. FDA certification and EU CE MDR certification. The announcement further states that overseas sales currently account for more than 80% of Zeldent’s total revenue, and that the company holds sales qualifications in Egypt, Saudi Arabia, and Vietnam.

According to previous reports by DENTALGOODNEWS (Leading Dental Industry Media, DGN), ST HILE has been active in the dental field recently: In April 2026, the company established a second-tier subsidiary, HILE Dental, through Ruisheng Biology to uniformly manage seven Jinboli Dental Clinic chain stores located in Yangzhou and Changzhou, which are expected to contribute approximately RMB 100 million in annual revenue. The company stated that this acquisition of Zerdun marks the extension and expansion of ST HILE's dental business into the dental restoration materials sector and is also beneficial for improving overall operational efficiency by integrating the industrial chain of "material R&D + smart manufacturing factory + terminal clinics."

Source: Announcement of *ST Haili Haili Biology regarding its controlling subsidiary's acquisition of equity in Hunan Zerdun New Materials Co., Ltd.

In terms of financial data, Zerdun achieved an operating revenue of RMB 72.8951 million and a Net Profit Attributable to Shareholders of the Parent Company of RMB 15.9668 million in 2025. The counterparty in this transaction has committed that Zerdun's audited cumulative net profit from 2026 to 2028 shall be no less than RMB 39 million. According to the company's calculations, the transaction is expected to increase net profit by approximately RMB 4.2 million in 2026.

According to previous reports by DGN, ST HILE was placed under delisting risk warning after its 2025 annual revenue fell below RMB 200 million and the company reported a substantial net loss. Against the backdrop of its ongoing integration of dental-related businesses, the company appears to be pursuing growth in scale and profitability through acquisitions and value-chain expansion.According to the announcement, the transaction has been approved by the Board of Directors and does not require submission to shareholders for approval.